This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES: Oligonucleotide & Peptide Therapeutics Content Hub
24/7 Access
Digital & In-Person
Menu

Anders Dahlén, Ph.D.
Associate Director, Oligo Chemistry Team at AstraZeneca
Speaker

Profile

Anders Dahlén studied Chemistry at Gothenburg University (Sweden) where he finalized his MSc in 2000, and his PhD on organometallic synthetic chemistry in 2005. Anders was recruited into the chemistry section of Cardiovascular, Renal and Metabolic Diseases, AstraZeneca R&D, in 2005 and was initially working in small molecule discovery before he joined the New Modalities Chemistry Team in 2013. During his time at AstraZeneca, Anders has held roles as Senior Scientist, Associate Principal Scientist, New Modalities Chemist and Team Leader. The past 4 years, Anders has been leading the efforts of the New Modalities Chemistry Team in CVRM, including work on peptides, oligos, conjugates, lipids for LNPs, 5’-caps, PNAs and PROTACs. Anders is also involved in several academic collaborations within the framework of the FormulaEx and MMBio networks. Anders is currently Team Leader of the Oligo Chemistry Team within Discovery Sciences. In his spare time, Anders enjoys orienteering and spending time with his family.

Agenda Sessions

  • Stealth Labeling of Oligonucleotides for Unperturbed Imaging

    On Demand - Premium Only